KRYS - Krystal Biotech, Inc.
| Previous Close | 17.27 |
| Open | 17.41 |
| Bid | 13.25 x 3200 |
| Ask | 19.71 x 900 |
| Day's Range | 17.16 - 17.99 |
| 52 Week Range | 8.03 - 17.99 |
| Volume | 70,080 |
| Avg. Volume | 38,898 |
| Market Cap | 180.418M |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.36 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.00 |
- GlobeNewswire•9 hours ago
Krystal Biotech to Present Update on KB103 Program for Treatment of Dystrophic Epidermolysis Bullosa at debra Care Conference 2018
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing topical and intradermal “off-the-shelf” treatments for rare dermatological diseases, today announces a presentation on the Company’s lead product candidate, KB103, the first-ever topically-applied gene therapy being developed for the treatment of dystrophic epidermolysis bullosa (DEB). The presentation will be delivered by Suma Krishnan, founder and chief operating officer of Krystal, at the biennial debra Care Conference, to be held in Chandler, Ariz., July 22-25, 2018.
- Zacks•3 days ago
Krystal Biotech (KRYS) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Krystal Biotech, Inc. (KRYS).
- Zacks•last month
Can the Rally in Krystal Biotech (KRYS) Shares Continue?
Krystal Biotech, Inc. (KRYS) has been on the move lately as the stock has risen by 24.5% in the past four weeks, and it is currently trading well above its 20-Day SMA
- ACCESSWIRE•2 months ago
Blog Exposure - Krystal Biotech’s KB103 Granted Fast Track Designation by FDA for Treatment of Dystrophic Epidermolysis Bullosa
LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Krystal Biotech, Inc. (NASDAQ: KRYS) ("Krystal"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KRYS as the Company's latest news hit the wire. On May 24, 2018, the Pennsylvania-based Company announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to the Company's lead product, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). KB103 is the first-ever topically-applied herpes simplex virus (HSV-1) based gene therapy engineered to deliver a human collagen protein to patients suffering from DEB.
- GlobeNewswire•2 months ago
U.S. FDA Grants Fast Track Designation for Krystal Biotech’s KB103 for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KB103 for the treatment of dystrophic epidermolysis bullosa (DEB). KB103 is the first-ever topically-applied herpes simplex virus (HSV-1) based gene therapy engineered to deliver a human collagen protein to patients suffering from DEB.
- GlobeNewswire•2 months ago
Krystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class Topical Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that the first patient has been dosed in the Phase 1/2, first in-human trial of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB). It is designed to evaluate the safety and tolerability of KB103 in subjects with the recessive form of dystrophic epidermolysis bullosa. DEB is a chronic, progressive and incredibly painful skin disease caused by mutations in the gene coding for type VII collagen, or COL7.
- GlobeNewswire•2 months ago
Krystal Biotech Presents In Vivo KB103 Data at the International Investigative Dermatology Conference that Show Human COL7 Incorporating into Anchoring Fibrils with Proper Structural Orientation
Lead product candidate, KB103, shown to successfully transfer COL7A1 gene and to correct recessive dystrophic epidermolysis bullosa. PITTSBURGH, May 09, 2018-- Krystal Biotech, Inc.,, a gene therapy company ...
- GlobeNewswire•2 months ago
Krystal Biotech Reports First Quarter 2018 Financial Results and Provides Corporate Update
“To date, 2018 has been marked by significant progress for Krystal Biotech, including clearance of the KB103 IND by the FDA for the treatment of dystrophic epidermolysis bullosa (DEB), granting of the U.S. composition of matter patent covering HSV vectors and methods of using the same to treat skin diseases, and the Company receiving Orphan Medicinal Product Designation in Europe for KB103,” said Krish S. Krishnan, chief executive officer of Krystal Biotech.
- GlobeNewswire•3 months ago
Krystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech Inc., ("Krystal") (KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces the clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for lead product candidate KB103. KB103 is the first-ever topical herpes simplex virus (HSV-1) based gene therapy engineered to deliver a human collagen protein to patients suffering from dystrophic epidermolysis bullosa (DEB).
- ACCESSWIRE•3 months ago
Wired News - Krystal Biotech's Lead Product Candidate, KB103, for Treatment of DEB Receives Orphan Medicinal Product Designation in Europe
LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on Krystal Biotech, Inc. (NASDAQ: KRYS) (''Krystal''). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KRYS as the Company's latest news hit the wire. On April 19, 2018, the Company announced that the European Medicines Agency (EMA) granted the Orphan Medicinal Product Designation (OMPD) for its lead product KB103, a gene therapy candidate for the treatment of Dystrophic Epidermolysis Bullosa (DEB).
- GlobeNewswire•3 months ago
Krystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa
KB103 represents the first investigational HSV-1 based gene therapy for the severe skin disorder dystrophic epidermolysis bullosa to receive this designation. KB103 previously received Orphan Drug Designation ...
- GlobeNewswire•3 months ago
Krystal Biotech Presents Their Skin TARgeted Delivery Platform at the World Orphan Drug Congress USA
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing “off-the-shelf” treatments for rare dermatological diseases, today announces a presentation on the Company’s proprietary technology, the Skin TARgeted Delivery Platform, or the STAR-D platform. The presentation will take place at the annual World Orphan Drug Congress USA, being held in Oxon Hill, Maryland, April 25-27, 2018.
- Simply Wall St.•9 months ago
Is Krystal Biotech Inc (KRYS) Still A Cheap Healthcare Stock?
Krystal Biotech Inc (NASDAQ:KRYS), a USD$114.55M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence ofRead More...
- GuruFocus.com•10 months ago
Krystal Biotech Inc (KRYS) President and CEO Krish S Krishnan Bought $1,000,000 of Shares
President and CEO of Krystal Biotech Inc (NASDAQ:KRYS) Krish S Krishnan bought 100,000 shares of KRYS on 09/22/2017 at an average price of $10 a share.
- 24/7 Wall St.•10 months ago
IPO News This Week: Roku, PQ Group Lead 7 Offerings Due Out
Seven IPOs are scheduled to hit the public markets this week, including video streaming service Roku and specialty chemicals firm PQ Group, both valued at more than $1 billion before their IPOs.
